Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

A phase I clinical trial of irinotecan and carboplatin in patients with extensive stage small cell lung cancer.

Crabb SJ, Bradbury J, Nolan L, Selman D, Muthuramalingam SR, Cave J, Johnson PW, Ottensmeier C.

Chemotherapy. 2012;58(4):257-63. doi: 10.1159/000341274. Epub 2012 Aug 15.

PMID:
22907396
2.

Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.

Chen G, Huynh M, Fehrenbacher L, West H, Lara PN Jr, Yavorkovsky LL, Russin M, Goldstein D, Gandara D, Lau D.

J Clin Oncol. 2009 Mar 20;27(9):1401-4. doi: 10.1200/JCO.2008.20.2127. Epub 2009 Feb 9.

3.

Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.

Ishimoto O, Sugawara S, Inoue A, Maemondo M, Nukiwa T.

Respir Investig. 2015 Jul;53(4):156-60. doi: 10.1016/j.resinv.2015.02.006. Epub 2015 May 4.

PMID:
26100175
4.

Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.

Sato M, Ando M, Minami H, Ando Y, Ando M, Yamamoto M, Sakai S, Watanabe A, Ikeda T, Sekido Y, Saka H, Shimokata K, Hasegawa Y.

Cancer Chemother Pharmacol. 2001 Dec;48(6):481-7.

PMID:
11800029
5.

A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.

Okamoto H, Naoki K, Narita Y, Hida N, Kunikane H, Watanabe K.

Lung Cancer. 2006 Aug;53(2):197-203. Epub 2006 Jun 15.

PMID:
16781005
6.

Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.

Charpidou A, Tsagouli S, Tsimpoukis S, Vassias A, Makrilia N, Stratakos G, Gkiozos I, Syrigos K.

Anticancer Drugs. 2010 Jul;21(6):651-5. doi: 10.1097/CAD.0b013e3283393718.

PMID:
20386306
7.

Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

Spigel DR, Hainsworth JD, Simons L, Meng C, Burris HA 3rd, Yardley DA, Grapski R, Schreeder M, Mallidi PV, Greco FA; Minnie Pearl Cancer Research Network.

J Thorac Oncol. 2007 Sep;2(9):854-61.

8.

Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.

Briasoulis E, Golfinopoulos V, Karina M, Papakostas P, Pavlidis N, Fountzilas G.

Anticancer Drugs. 2010 Sep;21(8):785-9. doi: 10.1097/CAD.0b013e32833d5ec0.

PMID:
20647930
9.

A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.

Okishio K, Mio T, Kawahara M, Yoshioka H, Yanagihara K, Daimon T, Furuse K.

Jpn J Clin Oncol. 2012 May;42(5):387-93. doi: 10.1093/jjco/hys028. Epub 2012 Mar 19.

PMID:
22430871
10.

A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.

Horn L, Zhao Z, Sandler A, Johnson D, Shyr Y, Wolff S, Devore RF, Laskin J.

Clin Lung Cancer. 2011 May;12(3):161-5. doi: 10.1016/j.cllc.2011.03.013. Epub 2011 Apr 27.

PMID:
21663858
11.

Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.

Spigel DR, Greco FA, Zubkus JD, Murphy PB, Saez RA, Farley C, Yardley DA, Burris HA 3rd, Hainsworth JD.

J Thorac Oncol. 2009 Dec;4(12):1555-60. doi: 10.1097/JTO.0b013e3181bbc540.

12.

Phase I. Trial of irinotecan plus carboplatin in two dose schedules.

Jones SF, Burris HA 3rd, Hainsworth JD, Yardley DA, Raefsky EA, Miranda FT, Kuzur ME, Willcutt NT, White MB, Greco FA.

Oncology (Williston Park). 2003 May;17(5 Suppl 5):36-40. Review.

PMID:
12800605
13.

Phase I dose escalation study of carboplatin to a fixed dose of irinotecan as first-line treatment of small cell lung cancer.

Schmittel A, Schulze K, Hütter G, Krebs P, Thiel E, Keilholz U.

Onkologie. 2004 Jun;27(3):280-4.

PMID:
15249718
14.

A German multicenter, randomized phase III trial comparing irinotecan-carboplatin with etoposide-carboplatin as first-line therapy for extensive-disease small-cell lung cancer.

Schmittel A, Sebastian M, Fischer von Weikersthal L, Martus P, Gauler TC, Kaufmann C, Hortig P, Fischer JR, Link H, Binder D, Fischer B, Caca K, Eberhardt WE, Keilholz U; Arbeitsgemeinschaft Internistische Onkologie Thoracic Oncology Study Group.

Ann Oncol. 2011 Aug;22(8):1798-804. doi: 10.1093/annonc/mdq652. Epub 2011 Jan 25.

PMID:
21266516
15.

Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.

Spigel DR, Greco FA, Rubin MS, Shipley D, Thompson DS, Lubiner ET, Eakle JF, Quinn R, Burris HA, Hainsworth JD.

Lung Cancer. 2012 Aug;77(2):359-64. doi: 10.1016/j.lungcan.2012.03.009. Epub 2012 May 3.

PMID:
22560921
16.

Combination chemotherapy of alternating etoposide and carboplatin with weekly administration of irinotecan and cisplatin in extensive-stage small-cell lung cancer.

Yoshimura A, Noro R, Miyanaga A, Mizutani H, Kosaihira S, Minegishi Y, Seike M, Hino M, Ando M, Nomura K, Okano T, Kobayashi K, Gemma A; East Japan Chesters Group.

Anticancer Res. 2012 Oct;32(10):4473-8.

PMID:
23060575
17.

Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer.

Choong NW, Vokes EE, Haraf DJ, Tothy PK, Ferguson MK, Kasza K, Rudin CM, Hoffman PC, Krauss SA, Szeto L, Mauer AM.

J Thorac Oncol. 2008 Jan;3(1):59-67. doi: 10.1097/JTO.0b013e31815e8566.

18.

Population-based maximum tolerated dose of irinotecan and carboplatin.

Wild CA, Wang SE, Gandara DR, Lara PN Jr, Meyers FJ, Tanaka M Jr, Houston J, Lauder J, Lau DH.

Oncology (Williston Park). 2003 Jul;17(7 Suppl 7):11-6.

PMID:
12886868
19.

Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.

Pectasides D, Visvikis A, Kouloubinis A, Glotsos J, Bountouroglou N, Karvounis N, Ziras N, Athanassiou A.

Eur J Cancer. 2002 Jun;38(9):1194-200.

PMID:
12044505
20.

Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC.

Natale RB, Socinski M, Sandler A, Israel VP, Miller L.

Oncology (Williston Park). 2000 Jul;14(7 Suppl 5):29-34.

Supplemental Content

Support Center